Statin use during pregnancy: a systematic review and meta-analysis

References

• Thorogood M, Seed M, De Mott K. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG116(4), 478–479 (2009).
   PubMedGoogle Scholar
• Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ337, a2423 (2008).
   PubMed Web of Science ®Google Scholar
• Andrade SE, Raebel MA, Brown J et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol. Drug Saf.17(3), 240–247 (2008).
   PubMedGoogle Scholar
• Kulaga S, Zargarzadeh AH, Berard A. Prescriptions filled during pregnancy for drugs with the potential of fetal harm. BJOG116(13), 1788–1795 (2009).
   PubMedGoogle Scholar
• Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur. J. Clin. Pharmacol.64(11), 1125–1132 (2008).
   PubMed Web of Science ®Google Scholar
• Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr. Perinat. Epidemiol.18(2), 106–111 (2004).
   PubMedGoogle Scholar
• Napoli C, D’Armiento FP, Mancini FP et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest.100(11), 2680–2690 (1997).
   PubMed Web of Science ®Google Scholar
• Napoli C, Glass CK, Witztum JL, Deutsch R, D’Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet354(9186), 1234–1241 (1999).
   PubMed Web of Science ®Google Scholar
• Alkemade FE, Gittenberger-de Groot AC, Schiel AE et al. Intrauterine exposure to maternal atherosclerotic risk factors increases the susceptibility to atherosclerosis in adult life. Arterioscler. Thromb. Vasc. Biol.27(10), 2228–2235 (2007).
   PubMedGoogle Scholar
• Ness RB, Harris T, Cobb J et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N. Engl. J. Med.328(21), 1528–1533 (1993).
   PubMed Web of Science ®Google Scholar
• Van der Graaf A, Vissers MN, Gaudet D et al. Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring. Arterioscler. Thromb. Vasc. Biol.30(12), 2673–2677 (2010).
   PubMedGoogle Scholar
• Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Cochrane Handbook for Sytematic Reviews of Intervention (Version 5.0.1 Edition). Higgins JPT, Green S (Eds). The Cochrane Collaboration, London, UK (2008).
   Google Scholar
• Wells GA, Shea B, O’Connell D et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses (2011).
   Google Scholar
• Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br. J. Clin. Pharmacol.64(4), 496–509 (2007).
   PubMedGoogle Scholar
• Taguchi N, Rubin ET, Hosokawa A et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod. Toxicol.26(2), 175–177 (2008).
   PubMed Web of Science ®Google Scholar
• McGrogan A, Snowball J, De Vries CS. Statins and pregnancy outcomes: a cohort study in the GPRD. Pharmacoepidemiology18(Suppl. 1), S75–S76 (2009).
   Google Scholar
• Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res. A Clin. Mol. Teratol.73(11), 888–896 (2005).
   PubMed Web of Science ®Google Scholar
• Freyssinges C, Ducrocq MB. Simvastatin and pregnancy. Therapie51(5), 537–542 (1996).
   PubMedGoogle Scholar
• Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am. J. Med. Genet. A131(3), 287–298 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA. Maternal exposure to statins and risk for birth defects: a case-series approach. Am. J. Med. Genet. A146A(20), 2701–2705 (2008).
   PubMedGoogle Scholar
• Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod. Toxicol.18(4), 619–621 (2004).
   PubMed Web of Science ®Google Scholar
• Teelucksingh S, El-Youssef J, Sohan K, Ramsewak S. Prolonged inadvertent pravastatin use in pregnancy. Reprod. Toxicol.18(2), 299–300 (2004).
   PubMedGoogle Scholar
• Vagt A, Kastendieck C. Probable congenital anomaly after exposure to atorvastatin in early pregnancy. From the Bremen register of drug-related diseases. Tagliche Praxis41, 409–412 (2000).
   Google Scholar
• Seguin J, Samuels P. Fluvastatin exposure during pregnancy. Obstet. Gynecol.93(5 Pt 2), 847 (1999).
   PubMedGoogle Scholar
• Ghidini A, Sicherer S, Willner J. Congenital abnormalities (VATER) in baby born to mother using lovastatin. Lancet339(8806), 1416–1417 (1992).
   PubMed Web of Science ®Google Scholar
• Trakadis Y, Blaser S, Hahn CD, Yoon G. A case report of prenatal exposure to rosuvastatin and telmisartan. Paediatr. Child Health14(7), 450–452 (2009).
   PubMedGoogle Scholar
• Wise LD, Prahalada S, Robertson RT, Bokelman DL, Akutsu S, Fujii T. Simvastatin (MK-0733): oral teratogenicity study in rabbits. Yakuri to Chiryo39(2), 159–167 (1990).
   Google Scholar
• Tanase H, Asai M, Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rabbits. Jap. Pharmacol. Ther.15(12), 67–73 (1987).
   Google Scholar
• Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology50(6), 387–394 (1994).
   PubMedGoogle Scholar
• Lankas GR, Cukierski MA, Wise LD. The role of maternal toxicity in lovastatin-induced developmental toxicity. Birth Defects Res. B Dev. Reprod. Toxicol.71(3), 111–123 (2004).
   PubMedGoogle Scholar
• Henck JW, Craft WR, Black A, Colgin J, Anderson JA. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol. Sci.41(1), 88–99 (1998).
   PubMedGoogle Scholar
• Hrab RV, Hartman HA, Cox RH. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology50(1), 19–26 (1994).
   PubMedGoogle Scholar
• Tanase H, Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rats. Jap. Pharmacol. Ther.15(12), 45–56 (1987).
   Google Scholar
• Tanase H, Hirose K. Reproduction study of pravastatin sodium administered prior to and in the early stages of pregnancy in rats. Jap. Pharmacol. Ther.15(12), 37–44 (1987).
   Google Scholar
• Minsker DH, MacDonald JS, Robertson RT, Bokelman DL. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Teratology28(3), 449–456 (1983).
   PubMedGoogle Scholar
• Wise LD, Majka JA, Robertson RT et al. Simvastatin (MK-0733): oral teratogenicity study in rats. Pre- and postnatal observation. Yakuri to Chiryo39(2), 143–158 (1990).
   Google Scholar
• Elahi MM, Cagampang FR, Anthony FW, Curzen N, Ohri SK, Hanson MA. Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring. Hypertension51(4), 939–944 (2008).
   PubMed Web of Science ®Google Scholar
• Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology60(6), 356–364 (1999).
   PubMedGoogle Scholar
• Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv. Exp. Med. Biol.686, 349–364 (2010).
   PubMed Web of Science ®Google Scholar
• Scialli AR. 2005 Josef Warkany lecture: clinicians. Birth Defects Res. A Clin. Mol. Teratol.76(1), 1–6 (2006).
   PubMedGoogle Scholar
• Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J. Obstet. Gynaecol. Can.29(11), 906–908 (2007).
   PubMedGoogle Scholar
• Frias JL, Gilbert-Barness E. Human teratogens: current controversies. Adv. Pediatr.55, 171–211 (2008).
   PubMedGoogle Scholar
• Avis HJ, Hutten BA, Twickler MT et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? Curr. Opin. Lipidol.20(6), 484–490 (2009).
   PubMed Web of Science ®Google Scholar
• Gibb H, Scialli AR. Statin drugs and congenital anomalies. Am. J. Med. Genet. A135(2), 230–231 (2005).
   PubMedGoogle Scholar
• Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod. Toxicol.10(6), 439–446 (1996).
   PubMed Web of Science ®Google Scholar
• Macintosh MC, Fleming KM, Bailey JA et al. Perinatal mortality and congenital anomalies in babies of women with Type 1 or Type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ333(7560), 177 (2006).
   PubMed Web of Science ®Google Scholar
• Satpathy HK, Fleming A, Frey D, Barsoom M, Satpathy C, Khandalavala J. Maternal obesity and pregnancy. Postgrad. Med.120(3), E01–E09 (2008).
   PubMed Web of Science ®Google Scholar
• Brent RL, Beckman DA. The contribution of environmental teratogens to embryonic and fetal loss. Clin. Obstet. Gynecol.37(3), 646–670 (1994).
   PubMed Web of Science ®Google Scholar
• Edison RJ, Berg K, Remaley A et al. Adverse birth outcome among mothers with low serum cholesterol. Pediatrics120(4), 723–733 (2007).
   PubMed Web of Science ®Google Scholar
• Bertrand N, Dahmane N. Sonic hedgehog signaling in forebrain development and its interactions with pathways that modify its effects. Trends Cell Biol.16(11), 597–605 (2006).
   PubMedGoogle Scholar
• Napoli C, de Nigris F, Welch JS et al. Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation105(11), 1360–1367 (2002).
   PubMed Web of Science ®Google Scholar
• Palinski W, D’Armiento FP, Witztum JL et al. Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits. Circ. Res.89(11), 991–996 (2001).
   PubMedGoogle Scholar
• Palinski W, Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J.16(11), 1348–1360 (2002).
   PubMed Web of Science ®Google Scholar
• Napoli C, Witztum JL, Calara F, de Nigris F, Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ. Res.87(10), 946–952 (2000).
   PubMed Web of Science ®Google Scholar
• Kenis I, Tartakover-Matalon S, Cherepnin N et al. Simvastatin has deleterious effects on human first trimester placental explants. Hum. Reprod.20(10), 2866–2872 (2005).
   PubMed Web of Science ®Google Scholar
• Henshaw SK. Unintended pregnancy in the United States. Fam. Plann. Perspect.30(1), 242–249 (1998).
   Google Scholar
• Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic? Clin. Sci. (Lond.)96(4), 421–425 (1999).
   PubMed Web of Science ®Google Scholar
• Berge LN, Arnesen E, Forsdahl A. Pregnancy related changes in some cardiovascular risk factors. Acta Obstet. Gynecol. Scand.75(5), 439–442 (1996).
   PubMed Web of Science ®Google Scholar
• Amundsen AL, Khoury J, Iversen PO et al. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis189(2), 451–457 (2006).
   PubMed Web of Science ®Google Scholar
• Roes EM, Sieben R, Raijmakers MT, Peters WH, Steegers EA. Severe preeclampsia is associated with a positive family history of hypertension and hypercholesterolemia. Hypertens. Pregnancy24(3), 259–271 (2005).
   PubMed Web of Science ®Google Scholar
• Redecha P, van RN, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood113(17), 4101–4109 (2009).
   PubMed Web of Science ®Google Scholar
• Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS One5(10), e13663 (2010).
   PubMed Web of Science ®Google Scholar
• Castro LC, Avina RL. Maternal obesity and pregnancy outcomes. Curr. Opin. Obstet. Gynecol.14(6), 601–606 (2002).
   PubMed Web of Science ®Google Scholar
• Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: estimated rates and trends worldwide. Lancet370(9595), 1338–1345 (2007).
   PubMed Web of Science ®Google Scholar
• Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ315(7099), 32–34 (1997).
   PubMed Web of Science ®Google Scholar
• World Health Organization. National, regional, and worldwide estimates of stillbirth rates in 2009 with trends since 1995. WHO, Geneva, Switzerland (2011).
   Google Scholar